Complement-derived polypeptide C3adesArg as a mediator of inflammation at the blood-brain barrier in a new experimental cat model.
The effect of the complement-derived polypeptide C3adesArg as a mediator of inflammation in the central nervous system was examined. Twenty-five anesthetized cats received 4 mg of this polypeptide by intraventricular injection, 20 cats who served as controls received saline. Cerebrospinal fluid (CSF) was sampled 3 h after intraventricular injection and the brains were removed. For assessment of the permeability of the blood-brain barrier the CSF penetration of four antibiotics, which were given intravenously was measured. Five control animals were employed for each antibiotic (tobramycin, ampicillin, imipenem, fosfomycin), whereas six C3adesArg-treated animals were used for each antibiotic and seven for tobramycin. Besides CSF levels of glucose, the prostanoids 6-keto-prostaglandin F1 alpha, thromboxane B2 and prostaglandin E2 were measured. The morphological examinations in the CSF sediments and histological brain sections in the C3adesArg-treated animals disclosed a distinct inflammation with leptomeningeal and perivascular infiltration of polymorphonuclear granulocytes compared to normal findings in the controls. The CSF/serum ratios of all of the antibiotics were markedly elevated compared to controls, indicating a blood-brain barrier disruption. The levels of all prostanoids were significantly higher in the treatment group than in the control group, whereas the glucose levels were lower. These findings are in accordance with a granulocytic meningitis as seen in some infections at the acute stage. It is concluded that C3adesArg acts as a mediator of inflammation in the central nervous system.
Höllerhage
H G
HG
Neurochirurgische Klinik, Medizinische Hochschule Hannover, Federal Republic of Germany.
Walter
G F
GF
Stolke
D
D
D015121:6-Ketoprostaglandin F1 alpha / Q000134:cerebrospinal fluid; D000818:Animals; D001812:Blood-Brain Barrier / Q000187:drug effects*; D002415:Cats; D002552:Cerebral Ventricles / Q000502:physiology*; D003176:Complement C3 / Q000031:analogs & derivatives* / Q000494:pharmacology; D015926:Complement C3a / Q000031:analogs & derivatives*; D015232:Dinoprostone / Q000134:cerebrospinal fluid; D005947:Glucose / Q000134:cerebrospinal fluid; D007267:Injections; D008581:Meningitis / Q000134:cerebrospinal fluid / Q000139:chemically induced*; D009994:Osmolar Concentration; D013929:Thromboxane B2 / Q000134:cerebrospinal fluid
D003176:Complement C3; C044541:complement C3a, des-Arg-(77)-; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; D015926:Complement C3a; D005947:Glucose; D015232:Dinoprostone